PT  - JOURNAL ARTICLE
AU  - DAILA S. GRIDLEY
AU  - ADEOLA Y. MAKINDE
AU  - XIAN LUO
AU  - ASMA RIZVI
AU  - JAMES D. CRAPO
AU  - MARK W. DEWHIRST
AU  - BENJAMIN J. MOELLER
AU  - ROBERT D. PEARLSTEIN
AU  - JAMES M. SLATER
TI  - Radiation and a Metalloporphyrin Radioprotectant in a Mouse Prostate Tumor Model
DP  - 2007 Sep 01
TA  - Anticancer Research
PG  - 3101--3109
VI  - 27
IP  - 5A
4099  - http://ar.iiarjournals.org/content/27/5A/3101.short
4100  - http://ar.iiarjournals.org/content/27/5A/3101.full
SO  - Anticancer Res2007 Sep 01; 27
AB  - Background: Antioxidants have the potential to protect normal tissues against radiation-induced damage, but must not protect tumor cells during radiotherapy. The major objectives were to determine whether a metalloporphyrin antioxidant affects prostate tumor response to radiation and identify possible mechanisms of interaction. Materials and Methods: C57BL/6 mice with RM-9 tumor were treated with manganese (III) meso-tetrakis(1,3-diethylimidazolium-2-yl)porphyrin (MnTDE-2-ImP) and 10 gray (Gy) radiation. Tumor volume was quantified and a subset/group was evaluated for hypoxia-inducible factor-1α (HIF-1α), bone marrow-derived cell populations and cytokines. Results: The addition of MnTDE-2-ImP transiently increased tumor response compared to radiation alone. The group receiving drug plus radiation had reduced intratumoral HIF-1α and decreased capacity to secrete TNF-α, whereas production of IL-4 was increased. There were no toxicities associated with combination treatment. Conclusion: The results demonstrate that MnTDE-2-ImP did not protect the RM-9 prostate tumor against radiation; instead, radiation effectiveness was modestly increased. Possible mechanisms include reduction of radiation-induced HIF-1α and an altered cytokine profile. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved